Comparison of the Effectiveness of Oral and Intratympanic Corticosteroid Treatments in Patients Diagnosed With Sudden Sensorineural Hearing Loss

Launched by DR. LUTFI KIRDAR KARTAL TRAINING AND RESEARCH HOSPITAL · May 5, 2025

Keywords

ClinConnect Summary

This clinical trial is exploring the best way to treat sudden sensorineural hearing loss, which is a type of hearing loss that comes on quickly and affects one ear. The researchers want to find out if taking corticosteroid medication by mouth (oral) or receiving it through an injection in the ear (intratympanic) is more effective for patients. Participants will be divided into two groups: one will take oral medication daily for two weeks, while the other will receive the ear injections every other day for a total of four doses. Throughout the study, participants will visit the clinic several times for checkups and hearing tests.

To join this trial, you need to be at least 18 years old and have experienced sudden hearing loss in one ear within the last 72 hours. Your hearing loss should be significant enough that it affects your ability to hear certain sounds. However, some people cannot participate, such as those with certain medical conditions, previous ear surgeries, or a history of specific diseases. If you qualify and decide to take part, you’ll help researchers understand which treatment helps improve hearing better, which may benefit future patients with similar conditions.

Gender

ALL

Eligibility criteria

• Inclusion Criteria:
• • 18 years of age and older
• • Unilateral sudden sensorineural hearing loss that developed within 72 hours and has lasted for 14 days or less
• • Affected side PTA (500-100-2000-4000hz) should be over 50dB
• • Affected side should be at least 30dB lower than healthy side in 3 frequencies
• • Hearing should be symmetrical according to patient's statement before sensorineural hearing loss
• • If used, steroid use should be less than 10 days
• • Cerebellar and vestibular examination should be normal
• Exclusion Criteria:
• • Having a history of hearing-related surgery other than a ventilation tube
• • Having a history of previous hearing loss, fluctuating hearing or Meniere's disease, chronic inflammatory or suppurative ear disease or cholesteatoma, otosclerosis
• • Being under 18 or over 80
• • Having a history of physical-barotrauma
• • Presence of structural or retrocochlear pathology in the examination and imaging that would explain the unilateral hearing loss
• • Patients diagnosed with tuberculosis or receiving prophylactic tuberculosis treatment, diabetes mellitus, rheumatological patients, those with atherosclerotic disease, serious psychiatric patients, those receiving chemotherapy, radiotherapy or immunosuppressant treatment, pancreatitis patients, HIV, hepatitis C and B patients, those with chronic renal failure, substance abusers, those with active herpetic lesions, severe osteoporosis patients, those with hearing loss within 4 weeks after general anesthesia, those with a history of head and neck cancer.